- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00282243
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States
-
-
Colorado
-
Denver, Colorado, United States, 80262
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
-
Rochester, Minnesota, United States, 55905
-
-
New York
-
New York, New York, United States, 10029
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
-
-
Texas
-
Dallas, Texas, United States, 75246
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is currently receiving Prograf ® based immunosuppressive therapy for liver transplantation.
- Patient has stable whole blood trough level concentrations of Prograf® and is clinically stable
Exclusion Criteria:
- Patient has previously received an organ transplant other than a liver
- Patient is currently receiving sirolimus immunosuppression therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tacrolimus MR
After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study. Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons. |
Oral
Other Names:
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus
Time Frame: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
The area under the concentration-time curve was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state using the linear trapezoidal rule.
The AUC0-24 for tacrolimus was calculated as the sum of the AUC0-12 for the morning (0-12 hour) and afternoon (12-24 hour) doses.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Minimum Observed Concentration of Tacrolimus (Cmin)
Time Frame: Days 14 and 42 at 12 hours post-dose (tacrolimus) and Days 28 and 56 at 24 hours post-dose (for tacrolimus MR).
|
The trough (minimum) concentration of tacrolimus determined from the tacrolimus whole blood concentration value at the 12 hour post-dose concentration based on the evening dose (i.e., the 8 am concentration) for tacrolimus and the 24-hour time point post-dose for tacrolimus MR, prior to receiving the next dose.
|
Days 14 and 42 at 12 hours post-dose (tacrolimus) and Days 28 and 56 at 24 hours post-dose (for tacrolimus MR).
|
Patient Survival
Time Frame: From enrollment until the end of study (up to 60 months).
|
Patient survival was defined as any participant known to be alive at the time of analysis.
|
From enrollment until the end of study (up to 60 months).
|
Graft Survival
Time Frame: From enrollment until the end of study (up to 60 months).
|
Graft survival was defined as any participant who did not meet the definition of graft loss, where graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Multiple Rejection Episodes
Time Frame: From enrollment until the end of study (up to 60 months).
|
This analysis includes rejection episodes that were either confirmed by biopsy by the clinical site pathologist or were clinically treated.
|
From enrollment until the end of study (up to 60 months).
|
Number of Participants With Clinically Treated Acute Rejection Episodes
Time Frame: From enrollment until the end of study (up to 60 months).
|
A clinically treated acute rejection episode was any biopsy-confirmed or suspected rejection episode that was treated with immunosuppressive therapy.
|
From enrollment until the end of study (up to 60 months).
|
Number of Participants With Chronic Rejection
Time Frame: From enrollment until the end of study (up to 60 months).
|
Due to the low number of participants with biopsy-confirmed acute rejection episodes, chronic rejection was not analyzed.
|
From enrollment until the end of study (up to 60 months).
|
Number of Participants With Treatment Failure
Time Frame: From enrollment until the end of study (up to 60 months).
|
Treatment failure was defined as discontinuation of study drug for any reason.
Due to discontinuation of the study by the sponsor, treatment failure was not analyzed.
|
From enrollment until the end of study (up to 60 months).
|
Maximum Observed Concentration of Tacrolimus (Cmax)
Time Frame: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
The maximum concentration was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state, without interpolation.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Time to Maximum Observed Concentration of Tacrolimus (Tmax)
Time Frame: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Time to the first occurrence to reach the maximum concentration of tacrolimus was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state, without interpolation.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Percentage of Participants With Biopsy-confirmed Acute Rejection
Time Frame: From enrollment until the end of study (up to 60 months).
|
Biopsy-confirmed acute rejection (BCAR) is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the pathologist at the clinical site according to the 1997 Banff criteria for grading of acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I (Mild): Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II (Moderate): Rejection infiltrate, expanding to most or all of the triads; Grade III (Severe): Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
|
From enrollment until the end of study (up to 60 months).
|
Time to Event for Patient Non-survival
Time Frame: From enrollment until the end of study (up to 60 months).
|
For participants who died on study, the median number of days from first dose of study drug to death due to any cause.
|
From enrollment until the end of study (up to 60 months).
|
Time to Event for Graft Non-survival
Time Frame: From enrollment until the end of study (up to 60 months).
|
For participants with graft loss, the median number of days from the first dose of study drug to graft loss.
Graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Time to First Biopsy-confirmed Acute Rejection
Time Frame: From enrollment until the end of study (up to 60 months).
|
For participants with a biopsy-confirmed acute rejection (BCAR), the median number of days from the first dose of study drug to the date of biopsy confirmation.
BCAR is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the clinical site pathologist according to the 1997 Banff criteria for grading acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I: Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II: Rejection infiltrate, expanding to most or all of the triads; Grade III: Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
|
From enrollment until the end of study (up to 60 months).
|
Grade of Biopsy-confirmed Acute Rejection Episodes
Time Frame: From enrollment until the end of study (up to 60 months).
|
Biopsy-confirmed acute rejection (BCAR) is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the clinical site pathologist according to the 1997 Banff criteria for grading of acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I (Mild): Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II (Moderate): Rejection infiltrate, expanding to most or all of the triads; Grade III (Severe): Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
For participants with more than one biopsy-confirmed acute rejection episode, the worst case grade is reported.
|
From enrollment until the end of study (up to 60 months).
|
Number of Participants Receiving Anti-lymphocyte Antibody Therapy for Acute Rejection
Time Frame: From enrollment until the end of study (up to 60 months).
|
Steroid-resistant rejection episodes were treated with anti-lymphocyte antibodies.
If a participant had a histologically proven Banff Grade II or III rejection, they could be initiated on anti-lymphocyte antibody treatment per institutional practice.
|
From enrollment until the end of study (up to 60 months).
|
Primary Reason for Graft Loss
Time Frame: From enrollment until the end of study (up to 60 months).
|
The primary reason for graft loss was recorded by the Investigator.
Graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Change From Baseline in Alanine Aminotransferase (ALT)
Time Frame: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring alanine aminotransferase levels over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Change From Baseline in Aspartate Aminotransferase (AST)
Time Frame: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring aspartate aminotransferase levels over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Change From Baseline in Total Bilirubin
Time Frame: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring total bilirubin over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Safety as Assessed by Adverse Events, Laboratory Parameters and Vital Signs
Time Frame: From the first dose of tacrolimus MR formulation through the last dose day plus 10 days (approximately 60 months).
|
An adverse event is defined as any reaction, side effect or other untoward medical occurrence, regardless of the relationship to study drug which occurred during the conduct of a clinical study. Clinically significant adverse changes in clinical status, routine laboratory studies or physical examinations were considered adverse events. A serious adverse event was any adverse event occurring at any dose that resulted in any of the following outcomes:
|
From the first dose of tacrolimus MR formulation through the last dose day plus 10 days (approximately 60 months).
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Central Contact, Astellas Pharma US, Inc.
Publications and helpful links
General Publications
- Florman S, Alloway R, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27;83(12):1639-42. doi: 10.1097/01.tp.0000265445.09987.f1.
- Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Wisemandle K, Fitzsimmons W, First MR. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005 Mar;37(2):1211-3. doi: 10.1016/j.transproceed.2004.11.086.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-0-152
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
Clinical Trials on tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
University of British ColumbiaPaladin Labs Inc.RecruitingLiver Transplantation | Neurotoxicity | Tremor | Tacrolimus | ImmunosuppressionCanada
-
Limerick BioPharmaCompleted